ESMO Asia 2025 | The emerging role of TKI-immunotherapy combinations in solid tumors
Takao Fujisawa, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan, highlights the efficacy of VEGFR-targeting tyrosine kinase inhibitors (TKIs) in combination with immune checkpoint inhibitors (IO) for various cancer types. While this combination shows promise in certain cancers, such as renal cell carcinoma and hepatocellular carcinoma, its efficacy is limited in other cancer types, but patients with high VEGFR expression may be good candidates for VEGFR TKI or VEGFR TKI-IO combination therapy. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As you know, some of the VEGFR target TKIs show a good efficacy for metastatic tumors as a conventional therapy with immune checkpoint inhibitors, like the renal cell carcinoma or the hepatocellular carcinoma. But unfortunately, the other type of cancer types, in other cancer types, the IO and the TKI they should show unpromising efficacy so but regarding the opinion analysis of patients with high VEGFR expression show the good efficiency of the VEGFR TKI...
As you know, some of the VEGFR target TKIs show a good efficacy for metastatic tumors as a conventional therapy with immune checkpoint inhibitors, like the renal cell carcinoma or the hepatocellular carcinoma. But unfortunately, the other type of cancer types, in other cancer types, the IO and the TKI they should show unpromising efficacy so but regarding the opinion analysis of patients with high VEGFR expression show the good efficiency of the VEGFR TKI. So I think that these patients, like the VEGFR patients with VEGFR high-expression patients are a good candidate for the development of the VEGFR TKI or the VEGFR TKI-IO combination.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
